ophthalmology

News

Sandoz makes its first post-spinout acquisition

Newly independent drugmaker Sandoz has made its first acquisition since spinning out of Novartis last October, buying a brand from Coherus that will boost its position in

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

Outlook slumps as FDA rejects eye disease drug

Shares in Outlook Therapeutics cratered today after the FDA rejected the company's marketing application for its lead drug ONS-5010, a therapy for age-related macular dege

News

After earlier rejection, high-dose Eylea clears FDA

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the

R&D